$20MSeries D, 13 May 2026
Funds clinical and commercial development of the FloStent device for BPH.
- Amount
- $20M
- Stage
- Series D
- Announced
- 13 May 2026
- Lead
- Andera Partners
- Use of funds
- Funds clinical and commercial development of the FloStent device for BPH.
- Checked
- Announced by the company
- Source
- Rivermark Medical raises $20M Series D led by Andera Partners massdevice.com